29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results
Titel:
29P Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naive ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results
Auteur:
Tiseo, M. Popat, S. Kim, H.R. Ahn, M-J. Yang, J.C. Han, J-Y. Hochmair, M.J. Lee, K.H. Delmonte, A. Garcia Campelo, M.R. Kim, D-W. Griesinger, F. Felip, E. Califano, R. Spira, A.I. Gettinger, S.N. Lin, H.M. Liu, Y. Vranceanu, F. Camidge, D.R.